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Rates of nonmedical psychostimulant use among emerging adults have been previously 
examined using self-report, but rates among adolescents have not been well documented. 
Additionally, few studies have examined the relation of nonmedical psychostimulant use and 
sleep. One purpose of this study was to examine rates of nonmedical psychostimulant use and 
sleep among adolescents and emerging adults utilizing the same self-report measures. The 
second goal was to compare objective measures of sleep among emerging adult nonmedical 
psychostimulant users and non-users. 
Using an online survey adolescents (n=62) and emerging adults (n=583) were asked 
about past and current nonmedical use of psychostimulants and sleep quality, as measured with 
the Pittsburgh Sleep Quality Index. Emerging adults were more likely to use psychostimulants 
nonmedically than adolescents [χ2(1, N = 592) = 13.93; p < .001, odds ratio = 7.5]. Emerging 
adults (M = 7.73, SD = 3.58) also self-reported worse quality sleep than adolescents (M = 6.36, 
SD = 3.97)[F(1, 570) = 5.34, p < .05]. Additionally, adolescents reported significantly more 
average sleep per night in hours (M = 7.77, SD = 1.71) than emerging adults (M = 6.97, SD = 
1.51) [t (1, 644) = 3.90; p < .01]. 
Objective measures of sleep, using actigraphy, and of nonmedical use, using urinalysis, 
were obtained from a sub-set of 14 nonmedical using and 14 non-using emerging adults. Among 
users, total sleep time was significantly lower on nights preceding use (M = 310.71, SD = 
116.89) than on nights not preceding use (M = 419.63, SD = 87.69) [F (1, 79) = 15.06; p < 
0.001]. No difference was found between nights following use when compared to nights not 
following use.  
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This study confirms that emerging adults are more likely than adolescents to use 
psychostimulants nonmedically and that emerging adults report poorer sleep quality and shorter 
sleep times than adolescents. Additionally, it seems that emerging adult users utilize 
psychostimulants to compensate for shortened total sleep time on the previous night.   
SUPPORT: WVU Doctoral Student Research support (MCK); WVU Alumni Fund (MCK); 
WVU Behavioral and Biomedical Sciences Training Scholarship Research Award (MCK). 
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Overview of Abbreviations 
ADHD/ADD – Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder 
ADHD Rating Scale-IV – Attention Deficit Hyperactivity Disorder Rating Scale-IV 
ANOVA – analysis of variance 
ASCITUS – Adolescent Sleep, Caffeine Intake, and Technology Use Questionnaire 
AW-64 – Actiwatch-64, a brand of actigraph 
DASS – Depression Anxiety Stress Scale 
DEA – United States Drug Enforcement Administration  
DV – Dependent Variable 
GC/MS – Gas Chromatography/Mass Spectrometry 
GPA – Grade Point Average 
H – Hypothesis  
IV – Independent Variable 
M – Mean 
MANOVA – Multivariate Analysis of Variance 
PBI – Problem Behavior Inventory 
PDA – Personal Digital Assistant 
PSQI – Pittsburgh Sleep Quality Index 
RQ – Research Question 
SAT –  Scholastic Aptitude Test 
 
SD – Standard Deviation  
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Nonmedical Psychostimulant Use and Sleep among Adolescents and Emerging Adults 
The purpose of this study was to examine nonmedical psychostimulant use and sleep 
among adolescents attending high school and emerging adults attending college. A relation 
between nonmedical psychostimulant use and subjective measures of sleep quality was found in 
the pilot study for the current study. This study not only includes objective measures of sleep and 
psychostimulant use but also improves our understanding of the relation between sleep and 
nonmedical use of prescription stimulants from a developmental perspective by including both 
adolescents and emerging adults. 
Nonmedical Psychostimulant Use 
 For this study, “stimulants” are operationally defined broadly as drugs that increase 
alertness, activity, and mood such as caffeine and nicotine (Julien, Advokat, & Comaty, 2007). 
“Psychostimulants” are operationally defined for this study as a specific category of stimulants 
utilized for the treatment of Attention Deficit Hyperactivity Disorder and Attention Deficit 
Disorder (ADHD/ADD) such as methylphenidate (Ritalin), dl-amphetamine (Adderall), and d-
amphetamine (Dexadrine; Julien et al., 2007). ADHD/ADD is defined as a pattern of behaviors 
made up of hyperactive-impulsive behaviors and/or inattentive behaviors in several settings 
beginning before the age of seven (American Psychiatric Association [DSM-IV-TR], 2000).  
Each of the above drugs have been classified as Schedule II drugs by the United States Drug 
Enforcement Administration (DEA), meaning that while these drugs have been approved to treat 
some medical disorders, their abuse potential is high (Kollins, MacDonald, & Rush, 2001; 
United States DEA, 2008).  
Use of psychostimulant medications in ways that have not been medically indicated, 
including use of psychostimulants obtained by faking symptoms, (nonmedical psychostimulant 
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use) is problematic because it can lead to increased anxiety, increased blood pressure, and 
overdose resulting in death (Prudhomme White, Becker-Blease, & Grace-Bishop, 2006). 
Furthermore, nonmedical psychostimulant use has been linked to co-morbid and subsequent 
abuse of recreational drugs (Advokat, Guidry, & Martino, 2008; Barrett, Darredeau, Bordy, & 
Pihl, 2005; McCabe & Teter, 2007; Teter, McCabe, Cranford, Boyd, & Guthrie, 2005; Wu, 
Pilowsky, Schlenger, & Galvin, 2007).  
Though most research on nonmedical use has focused on prevalence rates and motives of 
emerging adults who use psychostimulant drugs without prescriptions, few studies have assessed 
sources through which nonmedical users obtain these drugs (Low & Gendaszek, 2002; Teter et 
al., 2005). There is evidence that patients diagnosed with ADHD/ADD divert their prescription 
medications by giving or selling them to friends and acquaintances (Arria et al., 2008; 
Darredeau, Barrett, Jardin, Pihl, 2007). Furthermore, emerging adults with valid psychostimulant 
prescriptions are often not compliant and engage in psychostimulant misuse, including taking 
higher than recommended doses or medicating too frequently (Arria et al., 2008; Darredeau et 
al., 2007). Methods of obtaining psychostimulant drugs, including diversion, were collected in 
the current study. Additionally, motives for using psychostimulants nonmedically, such as to 
increase alertness and to get high, which are common among college students (Teter et al., 
2005), were examined among both college and high school students in this study.  
Use of non-prescription stimulants, such as caffeine, have also been found to affect sleep 
and daytime functioning. Specifically, caffeine reduces total sleep time, and increases sleep 
latency (Karacan et al., 1976; Roehrs & Roth, 2008). Furthermore, regular use of even low doses 
of caffeine can have detrimental effects on sleep (Roehrs & Roth, 2008). Because caffeine use is 
quite common and is related to sleep disruption, caffeine use was assessed in the current study on 
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the survey via the Adolescent Sleep, Caffeine Intake, and Technology Use Questionnaire 
(ASCITUS) with all participant and through voice memos provided by objective participants 
only, outlined below (Calamaro, Mason, & Ratcliffe, 2009). The ASCITUS is a survey 
developed specifically to measure caffeine intake and includes typical caffeinated beverages, 
energy drinks of various sizes, and caffeinated foods such as Rocket Chocolates (Calamaro et al., 
2009). 
 Adolescents. 
 Overall, there is a paucity of research examining nonmedical psychostimulant use among 
adolescents. In one of the few studies examining nonmedical psychostimulant use among 
adolescents, Poulin found that 8.5% of children in grades 7, 9, 10, and 12 reported using 
psychostimulants non-medically during the previous year (Poulin, 2001). This study also 
determined that adolescents with legitimate psychostimulant prescriptions who misused their 
prescription were more likely to engage in drug diversion than those who used their medications 
as prescribed (Poulin, 2001). 
 Another study included a survey of school nurses about in-school administration of 
psychostimulants. A sharp decrease in at-school administration by nurses due to extended-release 
formulas of psychostimulants (for students with ADHD/ADD) was associated with a subsequent 
reduction in psychostimulant diversion, theft, and misuse (DuPont, Bucher, Wilford, & Coleman, 
2007). DuPont and colleagues (2007) note that development of extended-release formulas, 
allowing reduction of in-school administration might assist in increasing parental control of 
psychostimulant use. Increased parental control would mean that adolescents would not have 
such ready access to the drugs, curbing adolescents’ ability to use the drug nonmedically or 
divert the drug to other students. However, it is possible that parents do not control 
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administration of these medications as tightly as schools, particularly among adolescents, 
providing the potential for psychostimulant misuse and diversion. 
 A cross-sectional study of prescription and over-the-counter drug use among adolescent 
outpatients at a substance abuse facility over four  years demonstrated a significant increase in 
nonmedical use of methylphenidate from 2% to 12% (Marsh, Key, & Payne, 2000). Although 
use of other drugs such as marijuana, alcohol, and cocaine were also analyzed, the only drug 
showing a rise in use across time was methylphenidate (Marsh et al., 2000). A later study found 
that among adolescents admitted to an addiction treatment center, 23% reported lifetime non-
medical use of psychostimulants and 6% reported current misuse (Williams, Goodale, Shay-
Fiddler, Gloster, & Chang, 2004). Because these studies were conducted on samples of 
adolescents with substance-abuse problems, it is reasonable to expect rates of nonmedical 
psychostimulant use to be significantly lower in the general population. However, as noted 
above, similar prevalence rates have been found in public school systems (Poulin, 2001). 
 No study of nonmedically using adolescents considered motives for psychostimulant use. 
However, Williams and colleagues (2004) found that methylphenidate abuse was common in 
substance-abusing adolescents who had an eating disorder. In light of this finding and because a 
common side effect of psychostimulants use is weight loss, the current study included “weight 
loss” as a possible motive for nonmedical use in addition to the motives typically found in 
studies of emerging adults, discussed below (Barkely, McMurray, Edelbrock, & Robbins, 1990). 
 Emerging adults. 
 Most research on nonmedical psychostimulant use has focused on emerging adults in 
college settings from small liberal art schools (Babcock & Byrne, 2000) to mid-sized universities 
(Prudhomme White et al., 2006) to large universities (Teter, McCabe, Boyd, & Guthrie, 2003). 
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Prevalence rates of nonmedical psychostimulant use range from 5.3% to 20% (DuPont et al., 
2008; McCabe, 2008). Additionally, in a study of both college attending and community 
emerging adults and late adolescents, a lifetime nonmedical psychostimulant use prevalence rate 
of 5.5% was found, with students significantly more likely to use nonmedically than nonstudents 
(Wu et al., 2007). The findings of Wu and colleagues (2007) suggest a need for further research 
on nonmedical psychostimulant use among emerging adults attending college institutions, which 
was the goal of the current study. 
Several studies of nonmedical psychostimulant use by emerging adults have also 
investigated motives for using these drugs. Two of the most popular reasons for emerging adults’ 
nonmedical psychostimulant use are to improve concentration while working or studying, and 
for recreation (Barrett et al., 2005; DuPont, Coleman, Bucher, Wilford, 2008; Teter et al., 2003). 
Additionally, nasal administration or “snorting” of psychostimulants for recreational use is 
common at rates from 12.7% (Babcock & Byrne, 2000) to 50% (Barret et al., 2005 among 
nonmedical users). Such recreational use has a high abuse and increased risk for abusing other 
drugs (Kollins et al., 2001; McCabe & Teter, 2007; National Institute of Drug Abuse, 2006). 
Comorbid drug abuse among nonmedical psychostimulant users has also been reported (Advokat 
et al., 2008; Arria et al., 2008; McCabe, 2008; McCabe, Knight, Teter, & Wechsler, 2005; 
McCabe, Teter, & Boyd, 2006; Teter et al., 2005). Specifically, a link between non-medical 
psychostimulant use and increased rates of alcohol and marijuana use and dependence has been 
found in several cross-sectional studies (Arria, et al. 2008; McCabe & Teter, 2007; Teter, et al. 
2005) with nonmedical psychostimulant users reporting higher rates of comorbid drug use than 
college students who used other  drugs. However, no causal direction of nonmedical 
psychostimulant use and use of other drugs has been established. 
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Sleep and Medically Approved Psychostimulant Use 
 One understudied effect of nonmedical psychostimulant use is sleep disturbance. Several 
studies examining sleep among a variety of child and adult samples using medically indicated 
psychostimulants are reviewed before sleep and nonmedical psychostimulant use among 
adolescents and emerging adults is specifically addressed.  
 Children diagnosed with ADHD/ADD who are prescribed immediate-release forms of 
methylphenidate show disturbance in sleep onset and total sleep time (Corkum, Panton, Ironside, 
MacPherson, & Williams, 2008). However, adults with ADHD/ADD using methylphenidate 
show increased sleep efficiency and have subjective reports of more restorative sleep (Sobanski, 
Schredl, Kettler, & Alm, 2007). Moreover, sleep deprived participants without ADHD/ADD 
demonstrate an increased preference for methylphenidate; participants provided with only four 
hours in bed with preference assessed at 9:00 a.m., preferred methylphenidate over a placebo. 
When participants were permitted eight hours in bed, this finding was reversed, suggesting that 
among healthy adults desire for psychostimulants hinges on sleep deprivation regardless of 
whether psychostimulants affect sleep (Roehrs, Papineau, Rosenthal, & Roth, 1999). Military 
investigations have found that psychostimulants, specifically d-amphetamine and modafinil, are 
effective in combating sleepiness among adults and delaying sleep onset (Eliyahu, Berlin, 
Hadad, Heled, & Moran, 2007). 
 Adolescent sleep and psychostimulant use.  
 Adolescents tend to sleep less than children, though their need for approximately nine 
hours of sleep is about the same (Jenni & Carskadon, 2005). This reduction in sleep time has 
been attributed to a biological phase shift in adolescents’ circadian rhythm during puberty that 
drives them to go to sleep at later times than in childhood (Carskadon, Vierira, & Acebo, 1993; 
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Carskadon, Wolfon, Acebo, Tzischinsky, & Seifer, 1998). Adolescent sleep phase shift in 
conjunction with early school start times truncates the sleep period for many adolescents on 
school days and has been related to chronic sleep deprivation (Carskadon et al., 1998). 
Sleep deprivation among adolescents is of particular importance because it has been 
associated with poor academic performance measured with grades, achievement tests, ratings by 
teachers and examinations of neurocognitive functioning (Beebe, Rose, & Amin, 2008; 
Buckhalt, Wolfson, & El-Sheikh, 2009; Carney, Edinger, Meyer, Lindman, & Istre, 2006; 
Wolfson & Carskadon, 1998). A more immediate danger and public safety issue of sleep 
deprivation in this age group is drowsy driving. Without the typical eight hours of sleep and/or 
with prolonged continuous wakefulness (18-21 hours), slower reaction times and more driving 
errors occur (Hutchens et al., 2008; Philip et al., 2005). In fact, being awake continually for 17 
hours, which most people do on a daily basis, is equivalent to a blood alcohol concentration of 
0.05 (Dawson & Reid, 1997). The risks of drowsy driving are compounded because adolescents 
and young adults are at risk for drinking and driving, and among adults, legal levels of alcohol 
with extended wakefulness have been linked to higher accident rates than illegal levels of alcohol 
in well-rested individuals (Howard et al., 2007).  
Thus, the additional contribution of nonmedical psychostimulant use may compound 
these problems. Only our pilot work has previously included the relation between nonmedical 
psychostimulant use and sleep among emerging adults. The most closely related area regards 
adolescent and emerging adult sleep related to medically approved psychostimulant use, which is 
briefly reviewed here.  
 Among children and adolescents, d-amphetamine and methylphenidate use was 
associated with insomnia and sleep difficulty compared to a baseline period with no drugs used 
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to treat and placebo, respectively (Ahmann et al., 1993; Barkely et al., 1990; Efron, Jarman, & 
Barker, 1997). However, the relation between nonmedical psychostimulant use and sleep among 
adolescents not diagnosed with ADHD/ADD is unknown. 
 Emerging adult sleep and psychostimulant use. 
 Young adults, who take longer to fall asleep than middle age adults, sleep approximately 
7.5 hours - significantly less than adolescents, but significantly more than those 30 and over who 
sleep an average of 6.5 hours on weekdays and 7 hours on weekends (Geisler et al., 2006; 
Groeger, Zijlstra, & Dijk, 2004; National Sleep Foundation, 2009).   
  Using actigraphy, which is a method of examining sleep using recordings of motion, 
Boonstra and colleagues (2006) demonstrated that adults with unmedicated ADHD/ADD 
experienced longer sleep latency and lower sleep efficiency than control participants. When 
methylphenidate was administered, the ADHD/ADD adults experienced later bedtimes and 
shorter sleep durations but also demonstrated an increase in sleep consolidation (Boonstra et al., 
2006). These results suggest that although adults with ADHD/ADD have baseline sleep 
problems, some of those problems are exacerbated by methylphenidate use providing support for 
the notion that psychostimulants will be related to worse sleep parameters in nonmedical users 
than non-users. 
In conditions of purposeful sleep deprivation, shift work specifically, methamphetamine 
improved performance on motor tasks and subjective report of alertness (Hart, Ward, Haney, 
Nasser, Foltin, 2003). Though the current study examined sleep and psychostimulant use from 
the point of drug use leading to sleep problems, it is possible that sleep problems, such as 
intentional sleep deprivation due to studying, may lead to use of psychostimulant drugs. More 
evidence of the possible bi-directionality of sleep and drug use can be found in the impulsivity 
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literature. Experimental sleep deprivation has been linked to a propensity to engage in higher 
rates of delayed discounting, a measure of impulsivity, than non-sleep deprived emerging adults, 
and impulsivity, which is related to high rates of drug abuse, has been linked to high rates of 
insomnia (Carroll, Anker, Mach, Newman, & Perry, 2010; Reynolds & Shiffbauer, 2004; 
Schmidt, Gay, Ghisletta, & Van der Linden, 2010). This research could be used as evidence to 
argue that impulsivity leads to both sleep problems and drug abuse or that sleep deprivation leads 
to impulsivity and, therefore, subsequent drug abuse. The current study provided information 
examining the relation between sleep problems and prescription drug abuse. 
 Both objective and subjective measures of sleep and psychostimulant use were utilized in 
the present study. Specifically, self-report of sleep and sleep quality as well as psychostimulant 
use was collected from adolescents and emerging adults using online surveys. Among emerging 
adults, a sample of nonmedical users and a control sample had their sleep objectively monitored 
and had levels of psychostimulants used objectively measured. 
Statement of the Problem 
The purpose of this study was to examine nonmedical psychostimulant use and sleep 
among adolescents attending high school and emerging adults attending college. Additionally, 
this study included a measure of mood as it related to sleep and nonmedical psychostimulant use 
among adolescents and emerging adults. In all, the goal of this study was to provide an enhanced 
overview of nonmedical psychostimulant use among both adolescents and emerging adults as 
well as how nonmedical use of these drugs is associated with objectively recorded sleep. 
Research Questions (RQ) and Hypotheses (H) 
Research Questions for Nonmedical Psychostimulant Use. 
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RQ1: How do prevalence rates of nonmedical psychostimulant use differ between adolescents 
attending high school and emerging adults attending college? 
H 1 a: Emerging adults will report higher rates of nonmedical psychostimulant use than 
adolescents.  
Rationale for RQ1 hypotheses. 
Prevalence rates of nonmedical psychostimulant use by emerging adults are between 
5.3% and 20% (DuPont et al., 2008; McCabe, 2008). Only one study has measured prevalence 
rates of nonmedical use in adolescents, found to be 8.5%, which is within the use range of 
emerging adults (Poulin, 2001). However Arnett (2005) discussed emerging adults’ 
developmental contexts, such as identity formation and instability in life and residence, as a 
factor in explaining the high rate of drug use compared to other life-span periods. No study has 
looked at more than one cohort at a time nor has a single study included both emerging adult and 
adolescent samples using the same survey. Because emerging adults in college typically 
experience more autonomy than high school students and often cohabitate in dormitories with 
access to psychostimulants, we expect higher rates of non-medical psychostimulant use among 
emerging adults attending college than among adolescents attending high schools when 
examining these cohorts at the same time using the same survey and administration method.  
Research Questions for Subjective Sleep Data. 
RQ2: How will sleep quality differ for adolescent and emerging adult non-users and nonmedical 
users? 
H 2 a: Overall, adolescents will have poorer subjective sleep quality than emerging 
adults, as measured with the Pittsburgh Sleep Quality Index (PSQI).  
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H 2 b: For adolescents subjective sleep quality will be poorer for nonmedical users than 
non-users. 
H 2 c: For emerging adults subjective sleep quality will be poorer for nonmedical users 
than non-users. 
Rationale for RQ2 hypotheses. 
 First, a main effect of age is expected on the PSQI because adolescents are subject to a 
delayed sleep phase shift in addition to early school start times, which truncates the sleep period 
(Carskadon et al., 1993; Carskadon et al., 1998). Because sleep phase shift has been related to 
puberty, it is likely that emerging adults will not experience this shift as strongly (Carskadon et 
al., 1993). Additionally, college students are able to schedule their own classes at preferred times 
as opposed to adolescents, who are required to attend school at a set time. Because college 
students can self-schedule classes for later start times if they experience sleep phase shift and 
have more opportunities for naps, school start times do not necessarily encumber the sleep period 
and, thus, sleep quality.  
 Additionally, pilot data for the current study examining sleep and nonmedical 
psychostimulant use found that after accounting for a variety of demographic variables, 
nonmedical psychostimulant use was related to poorer sleep quality than in non-users. Therefore, 
we expect that for both age periods, psychostimulants will be related to poor sleep quality. An 
additional interaction of age and nonmedical psychostimulant use is expected with adolescent 
users experiencing the worst sleep quality due to normally occurring sleep phase shift, truncation 
of the sleep period by school start times, and the stimulant effects of nonmedical 
psychostimulant use (Carskadon et al., 1993; Carskadon et al., 1998). 
Research Questions for Objective Sleep Data 
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RQ3: How will objective sleep measures differ between emerging adults who use 
psychostimulants nonmedically and emerging adults who do not use psychostimulants? 
H 3 a: Total sleep time will be shorter for nonmedical psychostimulant users than for 
non-users. 
H 3 b: Sleep efficiency will be lower for nonmedical psychostimulant users than for non-
users. 
H 3 c: Sleep latency will be longer for nonmedical psychostimulant users than for non-
users. 
Rationale for RQ3 hypotheses. 
 Pilot data for the current study demonstrated that nonmedical use was related to poor 
overall subjective sleep quality, poor subjective sleep quality, and higher sleep disturbance than 
non-users. On average college students, regardless of nonmedical psychostimulant use status, 
scored above the threshold of poor sleep quality (Carney et al., 2006; Scott-Sheldon, 2008). 
However, even after accounting for a high base-rate of poor quality sleep in this age group, 
nonmedical psychostimulant users reported significantly poorer sleep quality than non-users in 
the pilot study. Because the PSQI and actigraphy have both been validated against 
polysomnography, the gold standard of sleep measurement, we expect that objective measures of 
sleep will be worse for nonmedical users than non-users. However, Boonstra and colleagues 
(2006), found that methylphenidate was related to consolidated sleep in a sample of adults 
diagnosed with ADHD/ADD, suggesting that sleep pressure is higher in psychostimulant users 
than when there is no presence of psychostimulants. Sleep pressure increases with extended 
periods of wakefulness, and we expect that psychostimulants will extend wake periods in users 
leading to longer sleep latencies and shorter total sleep times. 
Psychostimulant Use and Sleep 13 
 
 
Method 
Data were collected using two methods. For Phase I, self report information concerning 
prevalence and motives for nonmedical psychostimulants was collected from adolescents and 
emerging adults via an identity-protected online survey. Phase II actigraphy and survey data 
were collected from a) emerging adults who were currently using psychostimulants 
nonmedically and b) non-user controls. Phase II participants also completed the survey used for 
Phase I. 
Participants 
Phase I. 
Adolescent Group.  
Participants were recruited using the following methods: fliers posted and handed out in 
and around local high schools, businesses, malls, movie theaters, sporting events, YMCAs and 
Boys and Girls clubs; online advertising, groups, and personal contact on facebook.com; 
postings on local cable television channels; postings on multiple radio station websites; postings 
on various groups for teenagers (local 4-H, HI-Y, Future Farmers of America, YoungLife 
websites, dosomething.org) and their parents (Greater Morgantown Area Youth Commission, 
Morgantown Parent Zone, postings on West Virginia University eNews), multiple postings on 
craigslist.com, an opinion-editorial piece in the Dominion Post, multiple postings on 
Twitter.com, via word-of-mouth (emails to school clubs such as choir, at community events such 
as Morgantown Kids Day, by teachers of health and psychology classes at local high school, by 
group leaders at Adventure West Virginia, at summer camps, contacting West Virginia 
Governor’s Schools and Honor’s Leadership Academy, announcements to a local cross-country 
camp, and during sleep-focused talks given to five high school health classes). High school 
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students were invited to complete the survey online using surveymonkey.com. Consent and 
assent were obtained online in order to reduce subject burden. Each adolescent participant 
completing the survey was entered into a drawing for a $50 gift card (1 gift card randomly 
awarded for every 50 completed surveys). The winner of the $50 gift card was chosen by sorting 
the data file with adolescent participants at the beginning, putting the range into a random 
number generator, and finding the corresponding row to the random number. This recipient was 
chosen with fewer than 50 complete adolescent surveys. An Institutional Review Board 
amendment was submitted to improve participants’ chances of winning (one $20 gift card for 
every 15 completed surveys) and encourage higher response rates. Completed surveys were 
obtained from 12 participants between Institutional Review Board approval and the end of data 
collection, and so no $20 gift cards were awarded. Once data were downloaded and the winner 
was determined, a receipt for the gift card was mailed to the winner asking for what store the gift 
card would be preferred. The gift card was then sent and all names and addresses used to send 
gift cards were permanently deleted from the files to ensure subsequent identity protection.  
Emerging Adult Group.  
Participants were recruited via undergraduate psychology classes at West Virginia 
University using announcements about the study in their classes, word of mouth, and fliers 
advertising the study placed in the Life Sciences Building. Participant consent was obtained by 
providing a cover letter at the beginning of the online survey. To protect their identities, the 
emerging adult group did not provide identifying information such as names. College students 
received extra credit points in their undergraduate psychology class for participation in the study. 
Extra credit was shown to be an adequate compensation for college students in the pilot study. 
This compensation, awarded via the Sona system, which records the amount of time college 
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students spend participating in approved online surveys, was awarded to emerging adults 
completing the online survey. Records of time, without records of what studies students 
complete, are sent to instructors, who then provide students with extra credit. Though the Sona 
system was used to access the survey, the survey was completed via surveymonkey.com. 
Materials 
Psychostimulant Use and Sleep Survey. 
Research suggests no differences in responses for surveys concerning sensitive issues 
using paper versus anonymous online administration have been found (Uriell & Dudley, 2009). 
Furthermore, Uriell and Dudley (2009) examined paper and internet-based surveys and 
participant confidence that responses were, in fact, anonymous. Confidence levels were lower for 
the internet-based survey, however perceived lower anonymity levels did not appear to be related 
to response differences among the two survey administration methods (Uriell & Dudley, 2009). 
Therefore, for the current study online survey administration was used.  
Statistical power for survey.  
 We recruited 645 participants for this phase of the study, 583 college students and 62 
high school students. Using the Gpower program, a power analysis was conducted (Faul & 
Erdfelder, 1992). With an expectation of a large effect size (d = 0.40) a sample size of n = 19 per 
group (N = 76) was the goal to obtain adequate power = 0.80, when comparing adolescents to 
emerging adults and nonmedical users to non-users (adolescent non-users, adolescent 
nonmedical users, emerging adults non-users, emerging adults nonmedical users). This sample 
size is lower than the sample size necessary with the expectation of medium effect size (d = 0.25) 
which would be n = 54 per group (N = 324). Because prevalence rates of nonmedical users was 
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expected to be lower than medical users and non-users, target sample sizes were slightly 
increased from the number obtained using Gpower for a large effect size.  
The survey began with a section asking about demographic information, specifically 
participants’ year in high school or college, age, race and ethnicity, parents’ marital status, 
parents’ education, number of siblings, unweighted grade point average from the last grading 
period, Scholastic Aptitude Test (SAT) scores either with or without the written section, ACT 
scores, whether the participant had a set bedtime and what time, whether the participant had a job 
and how many hours per week, involvement in fraternities or sororities, living arrangement, and 
highest level of education the participant hoped to complete. 
Psychostimulant use. 
No survey regarding nonmedical use of psychostimulants has been validated. Thus, ours 
was a modified version of a survey previously developed for pilot data collection based on other 
surveys examining nonmedical psychostimulant use among college samples (Barrett et al., 2005; 
McCabe, Knight, et al., 2005; McCabe, Schulenberg, et al., 2005; Teter et al., 2005). This survey 
included measures of duration and frequency of use of a variety of psychostimulants as well as 
motives for use, routes of administration, and how the drugs were obtained. A reproduction of 
the entire survey is in Appendix A. 
Sleep. 
Sleep and sleep quality were measured using the Pittsburgh Sleep Quality Index (PSQI) 
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The PSQI consists of seven component 
scores (each ranging from 0 to3) that are summed for a global sleep quality score (range 0-21) 
reflecting the previous month. Higher scores indicate worse sleep quality, and a global PSQI 
score ≥5 is considered the clinical cutoff between good and poor sleep quality among adult and 
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college-age samples (Buysse et al., 1989; Carney et al., 2006). Components of the global sleep 
score measure sleep quality, sleep latency, and sleep duration, habitual sleep efficiency, sleep 
disturbance, use of over-the-counter and/or prescription sleep medications, and daytime 
dysfunction. A reproduction of the survey and scoring rubric is in Appendix B. 
 ADHD/ADD symptomology. 
ADHD/ADD symptomology was measured using the ADHD Rating Scale – IV (DuPaul, 
Power, Anastopoulos, & Reid, 1998). This measure was used both as a screening device for high 
ADHD/ADD symptomology for participants in Phase II and for data collection in the online 
survey for Phase I and Phase II. The ADHD Rating Scale-IV is an 18-item inventory measuring 
ADHD/ADD symptomology according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (American Psychiatric Association [DSM-IV-TR], 2000) criteria for 
ADHD/ADD. Kooij and colleagues (2008) did a comparison of several surveys measuring 
ADHD/ADD symptomology among adults and found that the ADHD Rating Scale-IV is an 
effective screening tool for ADHD/ADD symptomology with high reliability between reporters 
(Chronbach’s alpha was between .7-.8), good convergent validity, and good divergent validity 
(Kooij et al., 2008). 
Caffeine use. 
Caffeine use was determined using the ASCITUS, a survey developed specifically to 
measure caffeine intake, sleep, and technology use among adolescents (Calamaro et al., 2009). 
The ASCITUS lists 19 caffeinated beverages, from tea to energy drinks, for which responders 
can choose the size and number of the beverage or other caffeinated items such as Rocket 
Chocolates and caffeine pills consumed on an average day. Typical caffeine intake was 
determined by multiplying the daily quantity of each drink by its caffeine content and summing 
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for each participant. The caffeine content of each drink was determined using manufacturer 
websites (gathered in January of 2009) and participant report of drink size (Calamaro et al., 
2009).  
Mood 
Mood was measured using the Depression Anxiety Stress Scale (DASS; Lovibond & 
Lovibond, 1995) which is a 42-item instrument with subscales measuring symptoms of 
depression, anxiety, and stress for the previous week. Each item is scored on a 0-3 scale based on 
whether the responder marks “Did not apply to me at all,” “Applied to me to some degree, or 
some of the time,” “ Applied to me a considerable degree, or a good part of the time,” or 
“Applied to me very much, or most of the time.” Antony and colleagues (1998) examined the 
psychometrics of the DASS and found high reliability (Cronbach’s alphas were .97 for 
depression, .92 for anxiety, and .95 for stress). The DASS subscales were also highly correlated 
with other commonly used measures of depression, anxiety, and stress. The DASS has also been 
successfully used to examine levels of depression, anxiety, and stress among emerging adult 
samples (Bayram & Bilgel, 2008; Gudjonsson et al., 2008). Among adolescent samples the 
DASS has been shown to be useful in measuring factors of negative mood and physiological 
arousal (Duffy, Cunningham, & Moore, 2005). 
Risk-taking behaviors. 
Survey responders also completed the Problem Behavior Inventory (PBI). The PBI is a 
29-item instrument used to measure frequency for a variety of problem behaviors, such as theft, 
physical violence, and inappropriate behaviors during the previous 12 months. Participants mark 
whether they have engaged in that behavior “never,” “once or twice,” “3 or 4 times,” “ once a 
month,” “2-3 times a month,” “once a week,” “2-3 times a week,” or “almost every day” in the 
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previous year. Haynes and colleagues (2006) found that drug abusing adolescents who 
experienced insufficient sleep were more likely to report aggressive behaviors and thoughts than 
when they experienced adequate sleep. Another study by O’Brien and Mindell (2005) 
demonstrated that adolescents with sleep problems were more likely to engage in risk-taking 
behaviors. The results of these studies are particularly interesting within the context of the 
current study in that the drugs being abused by nonmedical users are stimulants, which could 
disrupt sleep and, thus, possibly make subsequent problem behaviors more likely.  
Phase II. 
Phase II used actigraphy to objectively measure sleep among emerging adults engaging in 
nonmedical psychostimulant use and controls with no history of psychostimulant use. Objective 
urinalysis was used to quantify drug use among participants.  
 Participants in Phase II were 28 college students: 14 college students who reported 
currently nonmedical psychostimulant use and 14 control students who reported no previous or 
current psychostimulant use. Recruitment advertisements were placed in public areas of 
university buildings and presented in undergraduate psychology and biology classes. 
Additionally, a short description of Phase II inclusion and exclusion criteria and contact 
information was provided at the end of the college student version of the Phase I survey. A brief 
verbal screen was used to determine inclusion criteria: age >18 and nonmedical psychostimulant 
use or nonuse and exclusion criteria: diagnosis of ADHD/ADD or diagnosis of a sleep disorder. 
Participants also completed the ADHD Rating Scale-IV; any participant scoring >9 was excluded 
and provided with a reference list for mental health and addiction resources due to 
psychostimulant status as a Schedule II drugs. Phase II participants completed the same online 
survey designed to examine the relation between stimulant use and sleep on the last day of the 
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study described above. Control participants were matched as closely as possible to nonmedical 
psychostimulant users on gender, ethnicity, year in school, housing, parent education, SAT/ACT 
scores, involvement in fraternities or sororities, whether the participant had a regular bedtime 
and, if so, what time, and whether the participant had a job and, if so, how many hours worked 
per week. When possible, nonmedical users recruited for the study were asked to refer a matched 
control. 
 Participants for this phase were administered informed consent and Health Insurance 
Portability and Accountability Act authorization. Additionally, a Certificate of Confidentiality 
was obtained from the National Institutes of Health and the National Institute on Drug Abuse 
providing protection to participants who disclose sensitive information about illicit nonmedical 
psychostimulant use by allowing researchers to avoid disclosing information about participants 
in any “Federal, State, or local civil, criminal, administrative, legislative, or other proceedings” 
(Confidentiality Certificate, 2009). Besides consent form, all forms and surveys identified the 
participant only by number, and all data were stored on password and firewall protected 
computers and/or in locking filing cabinets to protect participants’ identity. 
For this phase of the study, participants were compensated $50 for completing the one-
week protocol. Compensation was provided on a prorated scale with $10 in cash being paid on 
Days 2, 4, and 6 and $20 in cash being paid on Day 7 following confirmation of protocol 
adherence and return of hardware. One participant withdrew from the study early, and was 
compensated using the above prorated scale. 
Statistical power for actigraphy analyses. 
A Multivariate Analysis of Variance (MANOVA) was used to examine how users/non-
users differ on total sleep time, efficiency, and sleep onset latency. For the effect size found in a 
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previous study examining methylphenidate in nonmedical users using polysomnography (1.96) 
and alpha=0.05, we need 20 total participants (Roehrs et al., 1999). This means that with 20 
participants, statistical analyses would likely have enough power to avoid a Type II error, which 
would occur if results were statistically non-significant even though there are actual differences 
among the groups.  
Actigraphy. 
Participants in Phase II wore an actigraph continuously for one week. Each nonmedical 
user and matched control began the study on the same day, which was scheduled according to 
the nonmedical user’s preference. The purpose of this scheduling was to attempt to collect data 
during a time when the nonmedical user would be likely to use psychostimulants because 
students often use these drugs to study for exams or work on term papers rather than using 
psychostimulants on a regular basis (Dupont et al., 2008; Teter et al., 2005). During the study, 
nonmedical users were instructed to use psychostimulants as they typically would and non-users 
were asked to continue abstaining from psychostimulant use.  
An actigraph is a device used to identify sleep and wake periods and is worn on the 
participants’ non-dominant wrist. Actigraphy is a valid method for recording activity levels used 
to identify periods of sleep and wake in non-laboratory settings among both adolescents and 
adults (de Souza et al., 2003, Jean-Louis et al., 1996; Johnson et al., 2007; Sadeh & Acebo, 
2002). There are various scoring algorithms to differentiate between sleep and wake with 
polysomnography agreement rates ranging from 97-99% in normative samples (de Souza et al., 
2003; Jean-Louis et al., 1996). Because any period indicating motionlessness could be scored as 
a sleep period, a sleep/wake diary and a watch on/watch off diary were completed by each 
participant so that the researcher could determine whether a period of motionless was sleep.  
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Periods of sleep and wake were monitored with actigraphy. Participants in Phase II wore 
the Actiwatch-64 (AW-64) actigraph produced by Philips-Respironics (Mini Mitter) 
continuously for one week on their non-dominant wrist. Actigraphs work by coding movement 
mathematically using an accelerometer that detects movements as small as 0.05 g-force in the 
AW-64 (Mini Mitter, 2005). Movement is recorded in a cumulative manner for the epoch, or 
time period indicated. At the end of each epoch, the total amount of movement within that epoch 
period is stored. For this study, the actigraphs were set to collect movement data in 15-second 
increments, which is the highest resolution recording possible using this device. At this recording 
level, the AW-64 is able to collect and store movement data on 64 KB of memory for 11.3 days, 
which is in excess of the seven days necessary for this study. The AW-64 is also equipped with 
an event marker button, which participants were asked to push when they were in bed, ready to 
go to sleep. The dimensions of the AW-64 are 29 x 37 x 12, and it weighs 16 grams without the 
watch band (Mini Mitter, 2005). Data were analyzed using Actiware® Software Version 5.4. 
 Sleep/wake states. 
In order to score periods of sleep and wake, both actigraphy and the sleep/wake diary, 
described below, were utilized. The sleep period was determined using participant report of sleep 
onset and advancing in time to a period of two consecutive minutes (8 epochs) of no movement. 
The wake period was scored in the same way. Figure 1 clarifies how sleep and wake periods 
were scored. After wake and sleep periods were manually scored and checked, Actiware 
software 5.2 calculated total sleep time, sleep efficiency, and sleep onset latency as described 
below. Naps were categorized as any sleep period marked by the participant and scored by the 
researcher as sleep meeting the following criteria: a sleep period between the hours of 8:00 am 
and 12:00 am lasting fewer than 180 minutes (3 hours) with a subsequent and previous scored 
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sleep period lasting at least 270 minutes (4.5 hours). Unless noted, naps are not included in 
measures of sleep.  (Insert Figure 1 here.) 
Total sleep time.  
Total sleep time was determined by the Actiware software by calculating the number of 
epochs manually scored as sleep, described above, and multiplying that number by the epoch 
length, which was 15 seconds in this study. Each epoch was scored as sleep or wake based on 
amount of activity. The Actiware software measured not only the 15-second epoch being scored, 
but also the two minutes preceding and following that epoch. The activity count of each epoch of 
the preceding and following two minutes was multiplied by a set value (1/5 for the minutes 
directly preceding and following and 1/25 for the two minutes adjacent to the 1/5 value minutes). 
The activity count for the epoch being examined plus the activity for the preceding and 
proceeding two minutes was added and compared a medium level threshold value of 40. If the 
activity count was ≤ 40, the epoch was scored as sleep, and if the epoch was > 40, the epoch was 
scored as wake.  
Sleep Efficiency. 
 Sleep efficiency is a measure of how much of the time one spends in bed as compared to 
time sleeping, with higher efficiencies indicating more of the sleep period spent asleep. The 
Actiware software calculated sleep efficiency by dividing the total sleep time, described above, 
by the total amount of time between sleep onset and offset. This number was then multiplied by 
100 to determine the percent sleep efficiency.  
Sleep Onset Latency.  
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Sleep onset latency is the time between when sleep onset is marked with the Personal 
Digital Assistant (PDA) and when the sleep period began, according to actigraphy scoring of 
sleep periods, described above. 
Personal Digital Assistant. 
The brand of PDA used in this study was the Palm Zire 72. Software created with Bruner 
Consulting, Inc. specifically for use by our laboratory was downloaded onto each PDA. This 
software included electronic versions of a sleep diary and a watch on/off diary, outlined in more 
detail below. Electronic diaries were particularly useful because rates of protocol adherence are 
higher with electronic diaries than paper diaries (Stone, Shiffman, Schwartz, Broderick, & 
Hufford, 2002). Participants were instructed to mark each time they removed or put on the 
actigraph, when they were going to bed for the night, when they were waking up for the day, and 
the beginning and end of any nap. In addition to the diaries, the PDAs were equipped with a 
voice recorder that was utilized in the current study as a means for participants to note instances 
of nonmedical psychostimulant use. Specifically, participants were asked to make time and date 
stamped voice recordings noting the type of drug, quantity, and dosage (if known) of 
psychostimulants, methamphetamine, cocaine, marijuana, alcohol, and any caffeine consumed 
after 9:00 p.m. Participants were provided with a reminder card outlining expectations of 
sleep/wake diary use, watch on/off diary use, voice memo use, and event marker use. At the end 
of the data collection week, data from the PDA were downloaded as a Microsoft Excel file and 
voice recordings were transcribed as Microsoft Notepad files onto a password protected 
computer in a locked laboratory. Upon confirmation of data download, all files were deleted 
from the PDA, and once voice recordings were transcribed, the voice recordings were deleted 
from the computer. 
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Sleep and watch diaries.  
Participants were instructed to use the sleep/wake diary to record when they were going 
to bed for the night, when they awoke for the day, and when any naps were taken. These entries 
were then date and time stamped. There was also an option to provide post hoc recordings of 
sleep and wake times should the participant not mark sleep/wake in real time. Similarly, 
participants used the watch on/off diary to mark each time they removed or put on their AW-64. 
Post hoc entries were also available for the watch diary. These diaries, in conjunction with 
actigraph recordings, were used to identify sleep and wake periods for analyses.  
Urinalysis. 
Researchers met with participants daily to administer five-panel drug tests in the sleep 
laboratory in the Life Science Building, which houses a private bathroom, at participants’ 
convenience. Nonmedical psychostimulant usage or nonuse was verified with urine samples 
provided by participants daily with a five-panel Instant-View® brand Multi-Drug Screen Urine 
Test for amphetamine, methamphetamine, cocaine, opiates, and marijuana metabolites, providing 
either a positive or negative result for presence of each of those drugs. Five-panel urine test 
results were examined by the researcher to determine if the test is positive for each of the above 
drugs and results were recorded. On-site drug screens for amphetamines have been found to have 
between 83-95% sensitivity and between 98-100% specificity (Leino, Saarimies, Gronholm, & 
Lillsunde, 2001). The frequency with which urine samples were collected is due to the period of 
detection with urine samples, which is 1-3 days, depending on a variety of variables such as 
dosage, weight, and metabolism (Bogema, 1998; Erowid, 2008). A reproduction of the 
specifications for the five-panel tests can be found in Appendix C. 
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At the end of the week of data collection, researchers met with participants in the sleep 
laboratory to collect and download actigraphy systems to assure protocol compliance. Afterward, 
participants were escorted to the Clinical Chemistry Laboratory at West Virginia University 
Hospital where participants provided a urine sample for the gas chromatography/mass 
spectrometry (GC/MS) analysis. The GC/MS was used to detect the quantity of amphetamine 
metabolite present in participants’ urine. The GC/MS was conducted on the all Phase II 
participants and provided quantitative values of amphetamine, methamphetamine, 
methylenedioxyamphetamine (MDA), and methylenedioxymethamphetamine (MDMA, 
Ecstasy). A reproduction of the specimen requisition used by the Clinical Chemistry Lab is in 
Appendix D. 
Preliminary Analyses 
Before hypothesis testing begins, data were cleaned. Pairwise deletion of missing data 
was used in order to utilize all available data for each analysis. Skew and kurtosis were analyzed 
for each demographic variable to ensure a normal distribution and frequencies were analyzed for 
demographic variables.  
Main Analyses 
RQ1: How do prevalence rates of nonmedical psychostimulant use differ between adolescents 
attending high school and emerging adults attending college?  
 Analysis. 
 A two-tailed t-test was used to examine RQ 1. School status — high school or college — 
was the independent variable (IV) and rate of nonmedical use was the dependent variable (DV). 
RQ2: How does subjective sleep quality differ for adolescent and emerging adult non-users and 
nonmedical users? 
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 Analysis. 
 To examine RQ2, a factorial mixed analysis of variance (ANOVA) was conducted using 
age group (adolescent or emerging adult) as one independent variable (IV), use category 
(nonmedical user, non-user) as the second IV, and subjective sleep quality (global PSQI score) as 
the dependent variable (DV). 
Research Questions for Objective Sleep Data 
RQ3: How do objective sleep measures differ between emerging adults who use 
psychostimulants nonmedically and emerging adults who do not use psychostimulants? 
 Analysis.  
 A MANOVA was used to examine RQ3. Use category (nonmedical users, non-users) was 
the IV, and sleep parameters (total sleep time, sleep efficiency, sleep latency) were the DVs.  
Results 
Phase I 
 Log-on numbers for the online survey were 212 adolescents and 632 emerging adults. 
However, only 62 adolescents and 583 emerging adults completed the survey. As expected, 
emerging adults were significantly older (M = 20.25, SD = 2.03) than adolescents (M=16.16, SD 
= 1.34) [t (1, 649) = -16.44; p < .001; Cohen’s d = 2.38]. Demographic characteristics of 
adolescents and emerging adults can be found in Table 1. (Insert Table 1 here.) 
 Skew and kurtosis were calculated for all demographic and outcome variables of interest. 
Because of the relatively large sample size of Phase I, values above three were considered 
skewed or kurtotic (Field, 2005). Of these variables, PBI scores were skewed (5.82) and kurtotic 
(53.21), and daily caffeine intake (in milligrams) was both skewed (9.47) and kurtotic (137.18). 
Because the skew and kurtosis for both PBI and caffeine were in the same direction for both 
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adolescents and emerging adults, these variables were not transformed, allowing for easier 
interpretation of results. 
 Participants were categorized into psychostimulant non-users (n=513) (those with no 
ADHD/ADD diagnosis, no current or previous use of psychostimulants, and no prescription for 
psychostimulants), nonmedical users (n=79) (those with no ADHD/ADD diagnosis, no 
prescription for psychostimulants, and current or previous use of psychostimulants), medical 
users (n=62) (those with a diagnosis of ADHD/ADD, with a prescription for psychostimulants, 
and current or previous psychostimulant use), medical non-users (n=9) (those with a diagnosis of 
ADHD/ADD or with a prescription for psychostimulants, and no current or previous use of 
psychostimulants), and medical misusers (n=3) (those with a diagnosis of ADHD/ADD or with a 
prescription for psychostimulants who also endorsed any nonmedical motive for psychostimulant 
use). 
 To address RQ1, which examined whether prevalence rates of nonmedical 
psychostimulant use differ between adolescents attending high school and emerging adults 
attending college, school status was categorized as either being in high school or college. 
Participants were asked, for Adderall, Ritalin/Concerta, Dexedrine, and Provigil/Nuvigil, if they 
had used each drug and how many times, on average, they used each drug. Rates of use were 
calculated by adding the average doses of each drug taken per week. Only those participants 
classified as non-users or nonmedical users were included in these analyses. Adolescents and 
emerging adults did not differ on rates of use when users, non-users, and medical users were 
included within the adolescent and emerging adult groups [t (1, 445) = -1.81; p = .07]. 
 To further investigate whether emerging adults and adolescents differed on nonmedical 
use, a chi-square analysis was conducted for age group (adolescents, emerging adults) and use 
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category (non-users, nonmedical users). The rate of participant psychostimulant use differed by 
school status [χ2(1, N = 592) = 13.93; p < .001, odds ratio = 7.5] with emerging adults in college 
being 7.5 times more likely to use psychostimulants nonmedically than high school students 
according to an odds ratio. 
 To address RQ2, examining how subjective sleep quality differed for adolescent and 
emerging adult non-users and nonmedical users, only non-users and nonmedical users were 
included in the factorial mixed ANOVA conducted to compare the relation of age group 
(adolescent, emerging adult) and use category (non-user, nonmedical user) on sleep quality 
(global PSQI score). The main effect of age group [F(1, 570) = 5.34, p < .05; Cohen’s d = 0.36] 
was significant with adolescents (M = 6.36, SD = 3.97) reporting better sleep (as indicated by 
lower scores on the PSQI) than emerging adults (M = 7.73, SD = 3.58), contrary to our 
hypothesis. The main effect of use category [F(1, 570) = 8.34, p < .01; Cohen’s d = 0.42] on 
sleep quality was also statistically significant with users reporting poorer sleep (M = 8.83, SD = 
3.15) than non-users (M = 7.40, SD = 3.68). However, the interaction effects of age group and 
use category on sleep quality could not be determined because no adolescents were classified as 
a nonmedical user.   
 Because no adolescents were classified as non-users, they were excluded from the 
following analysis. An ANOVA was conducted to examine how subjective sleep quality (global 
PSQI) differed for use categories of emerging adults including ADHD/ADD diagnosed users of 
psychostimulants (non-users, nonmedical users, medical users). A significant effect of use 
category on sleep quality was found, F(1, 575) = 6.45, p < .01. Specifically, Bonferroni follow-
up tests demonstrated that non-users (M = 7.54, SD = 3.62) displayed significantly better sleep 
quality than nonmedical users (M = 8.83, SD = 3.15) (p < .05; Cohen’s d = 0.38) and better sleep 
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quality than medical users (M = 8.72, SD = 3.44) (p < .05; Cohen’s d = 0.33). Nonmedical users 
and medical users did not differ significantly on sleep quality. An independent samples t-test was 
used to examine average sleep time, as determined with a single item on the PSQI asking how 
many average hours of sleep for the previous month the respondent obtained, among adolescents 
and emerging adults. Adolescents reported significantly more average sleep per night (M = 7.77, 
SD = 1.71) than emerging adults (M = 6.97, SD = 1.51) [t (1, 644) = 3.90; p < .01; Cohen’s d = 
0.50]. 
 To determine whether use groups (non-users, nonmedical users, and medical users) 
differed on ADHD/ADD symptomology, an ANOVA with ADHD Rating Scale-IV scores as the 
DV was conducted. Medical non-users and medical misusers were not included in this analysis 
due to the low number of participants classified as each. The overall ANOVA, shown in Figure 
2, was significant [F(2, 644) = 20.19, p < .001], and Bonferroni posthoc analyses demonstrated 
significantly lower ADHD Rating Scale-IV scores among non-users (M = 10.13, SD = 8.30) than 
nonmedical users (M=13.65, SD = 8.82; Cohen’s d = 0.41) and significantly lower scores among 
non-users than medical users (M = 17.00, SD = 12.24; Cohen’s d = 0.66). No differences in 
ADHD Rating Scale-IV scores were found between nonmedical users and medical users, 
however, the trend of ADHD Rating Scale-IV scores could be used as support for the idea that 
nonmedical users might possibly be self-medicating ADHD/ADD symptoms. (Insert Figure 2 
here). 
Phase II 
 Data for Phase II were collected between January 29, 2010, and March 25, 2010. This 
period of time overlapped with the midterm of the spring semester. No nonmedical users were 
able to refer an appropriate matched control, so controls were recruited using flyers posted in 
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public areas of campus, advertisements in psychology classes, advertisements at the end of the 
online survey used for Phase I, and word of mouth. One potential participant for the using group 
was ineligible for the study due to ADHD/ADD diagnosis, and three potential participants (two 
for the using group and one for the control group) scored above nine on the ADHD Rating Scale-
IV and were excluded from participation.  
 On average, nonmedical users’ urinalysis visits were at 1:27 p.m., and non-users visits 
were, on average, at 1:47 p.m. Among the 14 users, eight participants (57.14%) had at least one 
five-panel urine screen positive for amphetamine, and nine participants (64.29%) had at least one 
self-report of psychostimulant use. Among users only, five-panel tests for amphetamine were 
positive on 14.6% of the days, an average of fewer than one positive amphetamine screen per 
participant (.9), and users self-reported psychostimulant use on 24.4% of nights, or an average of 
1.4 per user. For all participants in Phase II, self report of use or nonuse and five-panel urine 
screens for amphetamine matched on 94% of the days. On 4.2% of days, use of a 
psychostimulant was reported with no corresponding positive amphetamine screen on the same 
or subsequent day. In particular, one user reported taking Focalin (dexmethylphenidate) on two 
days, but had a negative urine screens, one user reported taking Adderall (dl-amphetamine) on 
two days with  negative urine screens, and a third user reported taking Concerta 
(methylphenidate) on five days with negative urine screens. It is possible that participants 
believed they were using a psychostimulant, but were, in fact, using a different drug. Finally, 
positive five-panel urine screens for amphetamine were found on 1.9% of days with no 
participant self-report of psychostimulant use, with one participant screening positive on two 
days and two participants screening positive on one day each. All participants who had a positive 
GC/MS had at least one prior five-panel screen for amphetamine and prior self-report of 
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psychostimulant use.  Of the 22 self-reported psychostimulant administrations, 16 (72.7%) 
occurred before 4:00 pm and six (27.3%) occurred after 4:00 pm. 
Twenty-eight emerging adults (14 users and 14 non-users) participated.  Users and non-
users did not differ significantly on any demographic variables (see Table 2). Participants’ 
sleep/wake patterns were objectively monitored for seven days and six nights via wrist 
actigraphy. Partial data from one participant who withdrew from the study after five days and 
four nights for personal reasons was included in analyses. Skew and kurtosis were calculated for 
all demographic variables and variables of interest. As with Phase I data, values above three 
were considered skewed or kurtotic (Field, 2005), and all variables were within this range.  
Acebo and colleagues (1999) suggest that for adolescents, five to seven nights of 
recording are necessary to determine various values of sleep measures. Three users and three 
non-users had fewer than five sleep onset latency scores due to non-adherence to protocol 
instructions to push the event marker on the actigraph upon getting into bed. Therefore, data 
from these six participants were excluded from sleep onset latency scores only. However, these 
participants did complete the PDA-based sleep diary, permitting analyses of total sleep time and 
sleep efficiency. 
 To address RQ3, which examined how objective sleep measures differed between 
emerging adults who use psychostimulants nonmedically and emerging adults who do not use 
psychostimulants, a MANOVA was conducted using status (nonmedical user, non-user) as the 
IV and nighttime sleep measures (total sleep time, sleep efficiency, and sleep latency averaged 
over the week) as the DVs. Using the Wilks’ lambda test statistic, the omnibus MANOVA was 
not significant [F(3, 19) = 0.34; p = 0.80].  
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 A MANOVA with Wilks’ lambda test statistic was used to examine the relation between 
sleep parameters (total sleep time and efficiency) and daily amphetamine results of the five-panel 
tests (positive or negative) among users only. Sleep onset latency was not included in these 
analyses due to the participant non-adherence to pushing the actigraph event marker, described 
above. When nocturnal sleep of all users was grouped according to nights following positive 
amphetamine urine screens versus nights following negative amphetamine urine screens (IV = 
positive, negative), there was not a statistically significant difference [F (2, 78) = 0.99; p = .38].  
 However, when all users’ nights of sleep were grouped according to night preceding a 
positive amphetamine urine screen (IV = positive, negative) and examined nocturnal total sleep 
time and sleep efficiency, the overall MANOVA with Wilks’ lambda test statistic was significant 
[F (2, 78) = 7.83; p < .01]. Follow-up ANOVAs showed no differences for sleep efficiency [F 
(1, 79) = 3.05; p = .09] on nights preceding a positive versus negative urine screen for 
amphetamine. However, total sleep time on nights preceding nonmedical psychostimulant use 
(M = 310.71, SD = 116.89) compared to nights not preceding nonmedical psychostimulant use 
(M = 419.63, SD = 87.69) was statistically significant [F (1, 79) = 15.06; p < 0.001; Cohen’s d = 
1.05].  
Similarly, when users were grouped according to self-report of psychostimulant use on 
individual days (IV = used, did not use) and examined for differences in same-night nocturnal 
total sleep time and sleep efficiency, the overall MANOVA with Wilks’ lambda test statistic was 
significant [F(2, 78) =  4.21; p < .05]. Again, follow-up ANOVAS showed no differences for 
sleep efficiency [F(1, 76) = .30; p = .58], but a significant difference was found for total sleep 
time in minutes among positive self-report nights (M = 347.86, SD = 102.67) and negative self-
report nights (M = 419.94; SD = 93.99) [F(1, 79) = 8.47; p < .01; Cohen’s d = 0.73]. 
Psychostimulant Use and Sleep 34 
 
 
To further investigate total sleep time differences, an ANOVA was conducted to examine 
whether non-users, users on nights following a positive amphetamine screen, and users on nights 
preceding a positive amphetamine screen differed on total sleep time. The overall ANOVA, 
outlined in Figure 3 , was significant [F(2, 27) =  3.91; p < .05], and post hoc tests with 
Bonferroni correction showed that total sleep time in minutes for non-users (M = 402.42, SD = 
47.79) was significantly higher than total sleep time in minutes for users on nights preceding a 
positive amphetamine screen (M = 280.66, SD = 135.36; Cohen’s d = 1.20). No group 
differences were found for total sleep time on nights following a positive amphetamine screen 
(M = 343.04, SD = 104.26). (Insert Figure 3 here.) 
 Seventeen participants (60.7%) had at least one scored nap period during the study, as 
defined in the Methods section. Of those participants who napped, the average number of naps 
for the week was 2.58 with an average nap time of 68.02 (SD = 40.47) minutes per nap. 
Nonmedical users and non-users did not differ on frequency of naps (χ2 (1, N = 28) = 4.00, p = 
.68) or duration of naps [t(44) = 1.53, p = .13]. Among users, naps were not more frequent for 
days when psychostimulants were used versus days when psychostimulants were not used as 
measured with a positive or negative five-panel urine screen (χ2 (1, N = 102), = .23, p = .64) or as 
measured with self-report of psychostimulant use (χ2 (1, N = 102) = .30, p = .59). Also, naps 
were not more frequent on days following a positive or negative amphetamine urine screen (χ2 
(1, N = 105) = .03, p = .87) or self report of psychostimulant use (χ2 (1, N = 106) = 1.01, p = .32).  
 All participants in Phase II completed the online survey administered to participants in 
Phase I. Group differences (users, non-users) for survey-based variables of interest (daily 
caffeine intake, overall scores on the ADHD Rating Scale-IV and PBI, and anxiety, stress, and 
depression scores on the DASS) were examined as seen in Table 3. Only anxiety and PBI scores 
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were significantly different for users and non-users, with users scoring higher than non-users on 
both measures. Higher anxiety scores on the DASS were correlated with longer sleep onset 
latency [r (23) = .61; p < .01], but not with total sleep time or sleep efficiency. PBI scores were 
not significantly correlated with any of the three sleep measures. 
(Insert Table 3 here.) 
Discussion 
Phase I 
 Consistent with the RQ1 hypothesis, emerging adults were much more likely to engage in 
nonmedical use than adolescents. The finding that emerging adults are more likely to use 
psychostimulants nonmedically than adolescents is in line with differences in use rates among 
adolescents and emerging adults found in previous research that examined these age groups 
separately (Advokat et al., 2008; Low & Gendaszek, 2002; Poulin, 2001). Additionally, that 
emerging adults were more likely to employ psychostimulants nonmedically is in line with 
literature noting an increased availability, accessibility, and use of drugs and alcohol in college 
settings (Arnett, 2005; Prudhomme White et al. 2006; White, Fleming, Kim, Catalano, & 
McMorris, 2008). Though the completion rate of the survey for adolescents was low, the finding 
that no adolescents were classified as nonmedical users is quite surprising. Adolescents using 
psychostimulants nonmedically are more likely than adolescents using psychostimulants 
medically to engage in comorbid use of cigarettes, alcohol, and marijuana (Poulin, 2001). 
However, it is likely that the adolescents who self-selected to complete the survey are 
fundamentally different from adolescents who logged into the survey and did not complete it. 
Perhaps rates of nonmedical psychostimulant use for adolescents who logged into the survey and 
prematurely exited it are higher than rates among completers.  
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 Furthermore, significant differences in sleep quality, as measured with the PSQI, were 
found with adolescents reporting better sleep quality than emerging adults, contrary to the first 
hypothesis for RQ2, and with non-users of psychostimulants reporting better sleep quality than 
nonmedical users, consistent with the third hypothesis for RQ2. These findings are in line with 
research demonstrating that college students often report insufficient sleep time and poor sleep 
quality (Carney et al., 2006; Forquer et al., 2008). Such sleep problems among college students 
have been linked to various health problems and risky behaviors such as drinking and smoking 
(Vail-Smith, Felts, & Becker, 2009). It is interesting that emerging adults report poorer sleep 
quality and significantly lower average sleep times than adolescents because adolescents 
experience a biological drive to stay up later and often experience sleep truncated due to school 
start times (Carskadon et al., 1993). Findings of lower sleep time and worse sleep quality among 
emerging adults than adolescents point to the need for research examining normative sleep phase 
shift among adolescents longitudinally and into emerging adulthood. Perhaps the biologically 
driven short sleep experienced in early adolescence becomes reinforced by environment (late 
night interactions with peers, studying, computer use, television) over time contributing to even 
shorter sleep during emerging adulthood. 
 We were unable to determine the interaction of age group and use because no adolescents 
reported nonmedical use. This lack of adolescent nonmedical users is likely a result of the low 
number of adolescents completing the online survey. Again, it might also be positive news that 
of those adolescents participating in this study, none reported nonmedical use.  
 Both medically approved users and nonmedical users reported significantly poorer sleep 
quality than non-users. This finding, in combination with the fact that both medically approved 
users and nonmedical users demonstrated significantly higher levels of ADHD/ADD symptoms 
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than non-users suggests that differences in sleep quality among these groups could be attributed 
to either psychostimulant use or to ADHD/ADD symptomology. Research has found that adults 
with diagnosed ADHD/ADD demonstrated better sleep efficiency and subjective sleep quality 
after treatment with psychostimulants compared to pre-treatment (Sobanski et al., 2008).  
Phase II 
For RQ3, it was hypothesized that nonmedical psychostimulant users would have shorter 
total sleep times, lower levels of sleep efficiency and longer sleep onset latency than non-users. 
In the examination of RQ3, no differences were found for total sleep time, sleep efficiency, or 
sleep latency among users and non-users of psychostimulants. In itself, this lack of significant 
findings for this analysis is interesting. This result suggests that overall those participants 
choosing to abstain from psychostimulant use are not experiencing significantly better or worse 
sleep than those participants using psychostimulants illicitly. It might be that any changes in the 
sleep measures attributable to psychostimulant use are so small that, when averaged with nights 
users did not use, those effects were washed out. However, it is possible that college students, 
regardless of drug use status, have such poor and disturbed sleep that any detrimental effects of 
psychostimulants on sleep are inconsequential, as suggested by other studies examining college 
students’ sleep (Carney et al., 2006; Forquer, Camden, Gabriau, & Johnson, 2008, Lund, Reider, 
Whiting, & Prichard, 2010).  A more nuanced interpretation of sleep time emerged from 
secondary data analyses. 
Surprisingly, in a separate analysis of sleep among users only, no differences were found 
in total sleep time or sleep efficiency for users on nights following a positive amphetamine 
screen versus nights following a negative amphetamine screen. However, a significant difference 
in sleep measures was found for nights following self-reported psychostimulant use. Total sleep 
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time was significantly shorter on nights following self-reported psychostimulant use than nights 
following no self-report of use. A review article by Banks and Dinges (2007) suggests that sleep 
debt accrued by obtaining seven or fewer hours of sleep on a regular basis is linked decrements 
in response time, cognitive performance, and health. College students are likely to be carrying a 
significant sleep debt (Carney et al., 2006). Therefore, what may seem like a small reduction in 
users’ sleep time might have real world ramifications. An additional analysis comparing total 
sleep time among non-users, users on nights following a positive amphetamine screen, and users 
on nights preceding a positive amphetamine screen demonstrated that non-users obtained 
significantly more total sleep time than users on nights preceding a positive screen. However, 
neither of these groups had significantly different total sleep times than users on nights following 
a positive amphetamine screen. One might suspect that some users take psychostimulants at 
night to prolong wakefulness and truncate the sleep period due to obligations the following day 
(class, work, etc.), which is not uncommon among adolescents and emerging adults (Carney et 
al., 2006; Wolfson & Carskadon, 1998). However, the majority of self-reported psychostimulant 
use occurred before 4:00 pm suggesting that users took the psychostimulants to compensate for 
poor or insufficient sleep on the previous night. Additionally, a significant difference in sleep 
measures for the night preceding a positive amphetamine screen versus all other nights was 
found among users. Specifically, on the night preceding a positive amphetamine screen, users’ 
total sleep time was lower than other nights during the study.   
It is curious that these users did not demonstrate statistically significant longer sleep 
times on nights after positive screens, which would indicate a rebound effect. Rather, it seems 
that the sleep lost when users take psychostimulants nonmedically is part of a larger sleep debt 
not being “paid off” which could have effects on daily functioning including test performance 
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(Carskadon et al., 2004; O’Brien & Mindell, 2005; Wolfson & Carskadon, 1998). This lack of 
sleep debt being “paid off” is supported by the fact that, among users, naps were no more likely 
on days when psychostimulants were taken or days following psychostimulant administration (as 
measured with a urine screen or self-report) than days when psychostimulants were not taken 
(again, as measured with a urine screen or self-report).  
Previous research has indicated that insufficient sleep among adolescents and young 
adults is related to poor grades, mood disturbance, decreased reaction times, and behavior 
problems (Carskadon, 1990; Carskadon et al., 2004; Dinges, et al., 1997; O’Brien & Mindell, 
2005; Wolfson & Carskadon, 1998). For Phase II of this study, users reported higher levels of 
problem behaviors and higher levels of anxiety than non-users, supporting those previous 
findings. Higher levels of problem behavior among users than non-users was not unexpected 
because, by definition, each participant enrolled as a nonmedical psychostimulant user was 
engaging in illicit drug use. Additionally, higher PBI scores among users than non-users might 
be driven by items concerning aggressive behaviors, as previous research has implied a relation 
between low total sleep time among drug users and aggressive thoughts and behaviors (Haynes 
et al., 2006). High levels of anxiety were also correlated with longer sleep latency. Though 
causation cannot be determined using the current data, it is possible that higher levels of anxiety 
exist among users leading to longer sleep latencies and, thus, poor sleep. Users may be utilizing 
psychostimulants to combat the daily dysfunction associated with this poor sleep. However, it is 
also possible that use of stimulants is causing high levels of perceived anxiety or that some other 
variable, such as stress from school, leads to high levels of anxiety and subsequent 
psychostimulant use. 
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Correspondence of participant self-report of psychostimulant use and subsequent five-
panel urine screens for amphetamine was quite high, and there were very few instances of 
positive urine screens for amphetamine with no participant self-report of use or self-report 
without a positive urine screen. Prior research indicated that when participants know that 
researchers have the results of urinalyses, they are much more likely to report use accurately 
(Hamid, Deren, Beardsley, & Tortu, 1999). Additionally, participants in Phase II of the study 
were informed about the Certificate of Confidentiality protecting their personal information 
including that of illegal drug use, which likely encouraged honest reporting. Future studies 
examining psychostimulant use would benefit from utilizing five-panel urine screens, which are 
relatively inexpensive, to ensure honest reporting among participants. Some participants self-
reported psychostimulant use without a corresponding positive urine screen. This lack of 
correspondence suggests that nonmedical users might be ingesting any number of drugs without 
knowing what they are taking, adding an addition level of risk to taking unprescribed 
psychostimulant drugs. 
No significant differences were found for ADHD/ADD symptomology, depression, 
stress, or grade point average (GPA) when psychostimulant users and non-users were compared. 
Because we screened for ADHD/ADD symptomology and matched on variables such as age, 
GPA, and gender, the lack of significant differences between users and non-users was expected. 
However, it is interesting to note that at the end of the study, users reported average ADHD 
Rating Scale-IV scores higher than the pre-study enrollment criteria cutoff of nine. Furthermore, 
users were no more likely than non-users to report high levels of mood disturbance in the form of 
stress or depression, as would be expected according to previous study results. However, these 
measures were completed by participants on the final day of the study. Future research in this 
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area would benefit from administering daily measures of mood disturbance, fatigue, and 
performance to better determine whether the low levels of total sleep time associated with 
nonmedical use has an effect on measures of daily functioning.  
Limitations 
The primary limitation of Phase I was the relatively small sample size of adolescents. 
Though many different methods and strategies to recruit high school students were used, it 
proved difficult to obtain complete data for these participants. Even with significant 
compensation, it was challenging getting adolescents to voluntarily complete the survey, which 
lasted approximately 30 minutes. The small sample size of adolescents resulted in a lack of 
adolescent participants reporting nonmedical use, which considerably limited our ability to 
adequately compare adolescent and emerging adult nonmedical users. Perhaps future studies 
would benefit by offering a smaller reinforcement guaranteed to each participant completing the 
survey. 
One major limitation of Phase II was the lack of experimental control. Ideally, both users 
and non-users would be recruited for this study, and would be put on an alternating schedule of 
psychostimulant use and nonuse. Examining nonmedical psychostimulant use experimentally 
would allow researchers to determine whether non-users would display patterns of sleep 
disturbance similar to that of users and vice versa. Additionally, the time course of 
psychostimulants for each participant could not be determined because of different dosages 
taken, which were often unreported or of time-release versions halved, in addition to the weight 
and tolerance of each participant. Each of these factors affecting time course contributed to the 
difficulty attributing differences in sleep measures to use or nonuse of psychostimulants.  
Furthermore, it would be interesting to include participants with high levels of ADHD/ADD 
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symptomology and participants with diagnosed ADHD/ADD to examine whether these two 
groups would demonstrate similar sleep patterns.  
Additionally, the cross-sectional nature of this study limits interpretation of some results 
such as findings concerning differences in anxiety levels among users and non-users and the 
correlation of high anxiety with longer sleep latencies. A longitudinal design might have allowed 
for an examination of the change in anxiety scores, sleep measures, and use over time, perhaps 
capturing variables linked to subsequent nonmedical medical use or protective factors related to 
nonuse of these drugs. It might also be interesting to include period measures of daily 
functioning, such as the psychomotor vigilance test, which is an objective measure of reaction 
times. Furthermore, had equipment been downloaded daily during each urinalysis visit, 
researchers would have been able to check PDAs and actigraphs for protocol adherence. For 
example, daily downloads would have provided an opportunity to check whether participants 
pushed the event marker upon lights out each night. Future studies should take this into 
consideration and base data analyses on number of usable nights of data. Because of this 
restriction, we lacked sufficient data to examine sleep onset latency among users.  
Summary 
 Subjective results support the idea that emerging adults are more likely than adolescents 
to use psychostimulants nonmedically. Moreover, emerging adults who use psychostimulants 
either medically or nonmedically experienced poorer sleep quality and higher levels of 
ADHD/ADD symptoms than emerging adults who did not use psychostimulants. Findings from 
the objective portion of this study suggest that when users experience shortened total sleep time, 
they use psychostimulants nonmedically to deal with the fatigue and daytime dysfunction that 
accompanies sleep loss. Perhaps there is a paradoxical effect of psychostimulant drugs on sleep 
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such that some sleep measures are improved among those diagnosed with ADHD/ADD using the 
drugs as prescribed – at appropriate times, in approved quantities, in the approved manner of 
administration – as suggested by Sobanski and colleagues (2007), but other sleep measures 
deteriorate when psychostimulants are used by those without ADHD/ADD and/or those with 
ADHD/ADD but not as prescribed – close to bedtime, in inappropriate quantities, administering 
the drugs in unapproved ways. In order to best understand this, future objectively based research 
in this area should include participants with an ADHD/ADD diagnosis who both use and do not 
use their prescribed drugs according to their prescription. 
In sum, no group differences were found on objective sleep measures (total sleep time, 
sleep efficiency, or sleep latency) among psychostimulant users and non-users. However, among 
users, total sleep time was shorter on nights following self-report of psychostimulant use 
compared to nights following self-report of nonuse. Total sleep time was also shorter among 
users on nights preceding a urine screen positive for amphetamine as compared to nights 
preceding a negative urine screen for amphetamine but not on nights following a positive screen. 
These results in combination with the fact that users generally reported administration of 
psychostimulants before 4:00 p.m. suggest that users take psychostimulant drugs to combat the 
detrimental effects of lower total sleep time on the previous night. 
This study adds to the current literature in the areas of psychostimulant misuse and sleep. 
Specifically, this study demonstrated differences in rates of nonmedical psychostimulant use and 
in sleep quality among adolescents and emerging adults measured concurrently and with the 
same measures, which had not been done before. Furthermore, the current study was the first to 
measure both sleep and nonmedical psychostimulant use objectively with emerging adults, thus 
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improving our understanding of the relation between sleep and nonmedical use of prescription 
stimulants among college students, who are at a great risk to engage in nonmedical use.   
Based on this and previous research, several new avenues of research examining both 
sleep and nonmedical psychostimulant use among adolescents and emerging adults needs to be 
considered. First, future studies utilizing objective measures of sleep and psychostimulants 
should include adolescents and emerging adults with a diagnosis of ADHD/ADD for a clearer 
picture of how these drugs relate to sleep measures. Additionally, studies including people with a 
diagnosis of ADHD/ADD should closely examine adherence to prescription details. For 
example, it would be interesting to understand differences in sleep measures and impulsivity 
among young people diagnosed with ADHD/ADD who take their prescription as instructed and 
young people who skip administrations and/or hoard their prescription for future use. 
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Table 1.  
Demographic Characteristics of Subjective Participants (Phase I) 
Variable   Adolescents   Emerging adults   χ2 
 (n=62) (n=583) 
Use category          51.51*** 
Non-user 56  (90.4%) 441  (75.6%) 
Nonmedical user   0    (0.0%)      76  (13.0%) 
Medical user   0    (0.0%)      61  (10.5%) 
Medical non-user   3    (4.8%)        5    (0.9%) 
Medical misuser   3    (4.8%)        0    (0.0%) 
Year in School          
Freshman 12  (19.4%)      59  (10.1%) 
Sophomore 14  (22.6%) 271  (46.4%) 
Junior 16 (25.8%) 143  (24.5%) 
Senior 20  (32.3%) 111  (19.0%) 
Gender            8.83** 
Female 38  (61.3%) 457  (78.1%) 
Male 24  (38.7%) 128  (21.9%) 
Ethnicity            2.87 
Caucasian 53  (86.9%) 539  (91.7%) 
African American   2    (3.3%)       20  (3.4%) 
Hispanic   1   (1.6%)         7  (1.2%) 
Other   5    (8.2%)       22  (3.7%) 
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Variable   Adolescents   Emerging adults   χ2 
 (n=62) (n=583) 
GPA             8.96 
3.5-4.0 34  (54.8%) 212  (36.1%) 
3.0-3.49 16  (25.8%) 205  (34.9%) 
2.5-2.99   9  (14.5%) 128  (21.8%) 
2.0-2.49   2    (3.2%)       36    (6.1%) 
Less than 2.0   1    (1.6%)        6    (1.0%) 
Fraternity or sorority            
Yes   0    (0.0%)       74  (12.8%) 
No 62 (100.0%) 506  (87.2%) 
Parental Marital Status          2.09 
Married 38  (61.3%) 365  (62.3%) 
Divorced 15  (24.2%) 151  (25.8%) 
Separated   0    (0.0%)       10    (1.7%) 
Never Married   9  (14.5%)       60  (10.2%) 
Father education level           1.42 
Some high school   4    (6.6%)       25    (4.3%)  
High school 17  (27.9%) 163  (27.8%) 
Some college 12  (19.7%) 118  (20.1%) 
College 15  (24.6%) 161  (27.4%) 
Post secondary 13  (21.3%) 115  (19.6%) 
Unknown   0    (0.0%)         5    (0.8%) 
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Variable   Adolescents   Emerging adults   χ2 
 (n=62) (n=583) 
Mother education level          7.50 
Some high school 1    (1.6%)       12    (2.0%)  
High school 10  (16.4%) 151  (25.7%) 
Some college 11  (18.0%) 117  (19.9%) 
College 18  (29.5%) 186  (31.7%) 
Graduate school 21  (34.4%) 119  (20.3%) 
Unknown   0    (0.0%)         2    (0.3%) 
Desired education level        25.15*** 
Some high school   2    (3.2%)         0    (0.0%) 
High school   0    (0.0%)         5    (0.9%) 
Some college   1    (1.6%)       25    (4.3%) 
College 20  (32.3%) 120  (20.4%) 
Graduate school 39  (62.9%) 438  (74.5%) 
Living arrangement  364.71*** 
With parents 56  (90.3%)       32    (5.4%) 
With other relative   2    (3.2%)         8    (1.4%) 
With legal guardian   2    (3.2%)         1    (0.2%) 
Independently   1    (1.6%) 448  (76.2%) 
Residence hall   1    (1.6%)       85  (14.5%) 
Sorority/fraternity   0    (0.0%)       14    (2.4%) 
* p<.05, ** p<.01, ***p<.001 
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Table 2. 
Comparison of Phase II Demographics for Users and Non-users with Frequencies and Percents 
     Users Non-users   χ2 
Variable     (n = 14)  (n = 14) 
Year in School         2.3 
Freshman   8  (57.1%)   9  (64.3%) 
Sophomore   2  (14.3%)   2  (14.3%) 
Junior   2  (14.3%)   0    (0.0%) 
Senior   2  (14.3%)   3  (21.4%) 
Gender          0.0 
Female 10  (71.4%) 10  (71.4%) 
Male   4  (28.6%)   4  (28.6%) 
Ethnicity          0.0 
Caucasian 13  (92.9%) 13  (92.9%) 
Other   1    (7.1%)   1    (7.1%) 
GPA           4.9 
3.5-4.0   3  (21.4%)   5  (35.7%) 
3.0-3.49   4  (28.6%)   2  (14.3%) 
2.5-2.99   7  (50.0%)   4  (28.6%) 
2.0-2.49   0    (0.0%)   2  (14.3%) 
Less than 2.0   0    (0.0%)   1    (7.1%) 
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 Users Non-users   χ2 
Variable    (n = 14)  (n = 14) 
Fraternity or sorority         2.2 
Yes   2  (14.3%)   0    (0.0%) 
No 12  (85.7%) 14 (100.0%) 
Parental Marital Status        1.7 
Married   7  (50.0%)   7  (50.0%) 
Divorced   6  (42.9%)   4  (28.6%) 
Separated   1    (7.1%)   2  (14.3%) 
Never Married   0    (0.0%)   1    (7.1%) 
Father education level         4.5 
Some high school   0    (0.0%)   1    (7.1%) 
High school   5  (35.7%)   6  (42.9%) 
Some college   3  (21.4%)   1    (7.3%) 
College   4  (28.6%)   6 (42.9%) 
Graduate school   2  (14.3%)   0    (0.0%) 
Mother education level        2.0 
Some high school   0    (0.0%)   1    (7.1%)  
High school   5  (35.7%)   3  (21.4%) 
Some college   3  (21.4%)   2  (14.3%) 
College   5  (35.7%)   7  (50.0%) 
Graduate school   1    (7.1%)   1    (7.1%) 
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 Users Non-users   χ2 
Variable   (n = 14)  (n = 14) 
Desired education level        1.3 
Some high school   0    (0.0%)   0    (0.0%)  
High school   0    (0.0%)   0    (0.0%) 
Some college   1    (7.1%)   0   (0.0%) 
College   5  (35.7%)   4  (28.6%)   
Post secondary   8  (57.1%) 10  (71.4%) 
Living arrangement         0.0 
Independently   5  (35.7%)   5  (35.7%) 
   Residence hall   9  (64.3%)   9  (64.3%)   
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Table 3. 
Comparison of Phase II Users and Non-users of Psychostimulants on Survey Variables 
Variable   Non-users (n=14) Users (n=14)  F     Cohen’s d 
 Mean (SD) Mean (SD) 
DASS-depression 3.00  (7.13) 3.14  (3.86) 0.04   
DASS-anxiety 1.21  (0.89) 4.86  (5.30) 6.42*  .96 
DASS-stress 3.86  (4.02) 8.00  (7.89) 3.01 
ADHD Rating Scale-IV 6.64  (4.96)  12.29  (9.93) 3.62 
PBI 5.14  (5.19)  13.50   (10.96) 6.65*  .97 
Daily Caffeine (mg)   465.21 (646.11)   492.40 (650.18) 0.01 
Note. DASS=Depression, Anxiety, and Stress Scale, PBI = Problem Behavior Inventory.   
*p < .05. 
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Figure 1. 
Diagram Denoting How Sleep and Wake Times were Marked on Actigraphy using the PDA-
based Sleep and Wake Diary   
 
Note. Each upward inflection represents activity level during a 15 second epoch as measured 
with an actigraph. Arrow 1 represents the time on the PDA marked as the beginning of the sleep 
period by the participant. To score the beginning of the sleep period, the researcher finds an eight 
epoch (two minute) period following Arrow 1. This period is represented with Arrows 2 and 3. 
The sleep period is then marked at the beginning of this eight epoch period (at Arrow 2).
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Figure 2. 
 ADHD/ADD Symptoms among Non-users, Nonmedical Users, and Medical Users of 
Psychostimulants 
   
Note. Error bars represent standard deviation.  
**p < .01, ***p < .001.  
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Figure 3.  
Comparison of Total Sleep Time for Non-users, Users on Nights Preceding Psychostimulant 
Use, and Users on Nights Following Psychostimulant Use 
 
Note. Error bars represent standard deviation. Total sleep time is measured in minutes for nights 
preceding or following use among users and is averaged across six nights for non-users. 
 *p < .05
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Appendix C 
Instant-View
® 
Multi-Drug Screen Urine Test Specifications 
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Appendix E 
 
No, really – the BEST and EASIEST brownies ever 
Warning: you will forsake boxed brownies forever. 
 
10 tbs. unsalted butter (1 ¼ sticks) 
1 ¼ cups sugar 
¾ cup + 2 tbs. unsweetened cocoa powder 
¼ tsp. salt 
½ tsp. vanilla extract 
2 eggs, cold 
½ cup flour 
2/3 cup nuts, optional 
 
Preheat oven to 325ºF. 
 
Melt butter in the microwave. Mix in sugar, cocoa, and salt. Allow mixture to cool a bit until it’s 
warm, but no longer hot. It might not be smooth at this point – that’s OK. With a wooden spoon* 
mix in vanilla. Then add the eggs one at a time until each is well incorporated. Next mix in the 
flour until you can’t see it anymore, and continue to beat it for 40 more strokes (Why? See: *). 
Then stir in nuts (or chocolate chips or whatever extra goodie you prefer; but trust me, these are 
divine without a bunch of extra stuff). 
 
Pour mixture into a greased or parchment lined 8x8 inch baking pan. Bake until toothpick 
inserted into center comes out clean (around 30 minutes, but start checking at 25 minutes). 
 
Once cooled, dig in. If you want a pretty presentation then you might want to place the brownies 
in the refrigerator until they are more solid to make slicing cleaner. 
 
*Why wooden? I don’t know. Baking is sometimes like graduate school, just do what you’re told 
because those people know more than you do. 
 
 
